Sartorius Stedim Experiencing Tough 2023 Reset, but Long-Term Story Intact

Sartorius Stedim Biotech, the bioprocess subsidiary of Sartorius AG, is a leading provider of single-use biopharmaceutical fermentation and fluid management solutions. Sartorius performs consultations and custom installations of biomanufacturing systems for its drugmaker clients, which include bioreactors, filtration and purification systems, and cell analysis systems. This equipment has high disposable consumable requirements, including single-use bioreactor bags, filters, tubes, and containers. The company’s proven expertise in single-use technology, or SUT, and the regulation-validated nature of biomanufacturing gives Sartorius an attractive razor-and-blades model and supports a wide economic moat.